ALX Oncology (ALXO) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ALX Oncology (ALXO) has outperformed Stablecoin Development (SDEV) over the past year, losing 38.3% versus a loss of 55.9%. Over five years, ALXO leads with a -98.1% price change compared with -99.9% for SDEV. ALX Oncology is the larger company by market cap ($155.6 million vs $104.8 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | SDEV |
|---|---|---|
| Share price | $1.13 | $2.03 |
| Market cap | $155.56M | $104.80M |
| 1-day change | -0.44% | -27.16% |
| YTD return | 0.00% | -90.14% |
| 1-year return | -38.25% | -55.87% |
| 5-year return | -98.08% | -99.92% |
| EPS (TTM) | $-1.13 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $99.75 |
| 52-week low | $1.05 | $0.78 |
| Distance from 52-week high | -57.71% | -97.97% |
| Analyst consensus | none | — |
| Avg. price target upside | +308.89% | — |
| Average volume | 1.02M | 11.42M |
| Shares outstanding | 138.28M | 51.75M |
| Employees | 48 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed SDEV by 17.6 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ALXO vs SDEV FAQ
Which is bigger, ALX Oncology or Stablecoin Development?
ALX Oncology (ALXO) is larger, with a market capitalization of $155.56M compared with $104.80M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, ALXO or SDEV?
ALXO returned -38.25% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.